rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MRNA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Moderna 600% YTD rally catches cold: What's next amid stock's downtrend?
      9h agoSeeking AlphaMRNA
      Moderna drops marking longest losing streak since 2024

      Moderna (MRNA) stock falls for a seventh session, the longest losing streak since November 2024, as analysts cite valuation concerns after the YTD rally. Read more here.

      9h agoSeeking AlphaMRNA
      Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity
      14h agoYahoo FinanceMRNA
      Moderna at Jefferies Global Healthcare Conference: oncology push builds
      15h agoInvesting.comMRNAJEF
      9 US Stocks With the Largest Fair Value Estimate Increases During Q3 Earnings
      20h agoMorningstarLITEMRNA
      Analysts Offer Insights on Healthcare Companies: Kardigan, Inc. (KARD), Moderna (MRNA) and Revvity (RVTY)

      Detailed price information for Moderna Inc (MRNA-Q) from The Globe and Mail including charting and trades.

      Nov 17The Globe and MailMRNARVTY
      Why is Moderna stock sliding today?
      Nov 17Investing.comMRNA
      Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
      Nov 17Yahoo FinanceAMGNGILDMRNAREGN
      JPMorgan raises Moderna stock price target on expense outlook
      Nov 17Investing.comMRNA
      Is Moderna's Cancer Vaccine a Game Changer for the Stock? | The Motley Fool

      The healthcare stock has hit multi-year highs this year amid positive results from its personalized cancer vaccine.

      Nov 16The Motley FoolMRNA
      Two ‘Best Stocks’ are pulling back from highs. Josh Brown on how to trade them from here

      Josh Brown and Sean Russo break down what's going on with these stocks.

      Nov 16CNBCMRNA
      Why is Moderna stock sliding today?
      Nov 16Investing.comMRNA
      Dr. Robert Langer, Co-Founder of Moderna, Joins PolarityBio’s Board of Directors
      Nov 16Yahoo FinanceMRNA
      Biotech Venture Firm Flagship Invests £100 Million in New UK Lab
      Nov 16BloombergMRNA
      Moderna president Stephen Hoge sells $11.7M in common stock
      Nov 15Investing.comMRNA
      Moderna chief legal officer to retire, transitional agreement details compensation
      Nov 13Investing.comMRNA
      Moderna, Inc. (MRNA) Analyst/Investor Day - Slideshow

      2026-11-13. The following slide deck was published by Moderna, Inc.

      Nov 13Seeking AlphaMRNA
      The Single Most Important Metric For Moderna Stock
      Nov 13Yahoo FinanceMRNA
      Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls
      Nov 13Yahoo FinanceMRNA
      The science of vaccines is rapidly advancing — despite the anti-vax movement

      Look at the promising data for Moderna and Merck’s experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.

      Nov 13MarketWatchMRNA
      What Invesco S&P 500 Equal Weight ETF (RSP) Sold: Moderna Leads on Nov. 11
      Nov 13Yahoo FinanceMRNAIVZRSP
      We have studies ongoing in five different tumor types, says Moderna CEO Stéphane Bancel

      Stéphane Bancel, Moderna CEO, joins 'Mad Money' host Jim Cramer to talk its partnership with Merck on a cancer treatment, expanding beyond vaccines, clinical trial data, and more.

      Nov 13CNBCMRNA
      GSK (LSE:GSK) Settles Key Vaccine Patent Case And Wins Broad Europe Injunction
      Nov 13Yahoo FinanceMRNAGSK
      Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook
      Nov 12Yahoo FinanceMRNA
      Why Is Moderna (MRNA) Joining A Global Benchmark And Publishing New Vaccine Data?
      Nov 12Yahoo FinanceMRNA
      The Next Chapter of mRNA

      Moderna, led by CEO Stéphane Bancel, is forging the future of mRNA with its new personalized cancer vaccine.

      Nov 12TimeBNTXMRNA
      Why Moderna Stock Dropped on Thursday | The Motley Fool

      Moderna promised 20% sales growth in 2026 -- but Wall Street wants 24%.

      Nov 12The Motley FoolMRNA
      Moderna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes.

      Moderna plans to reinvest in its pipeline, particularly oncology treatments like its personalized cancer vaccine. But investors are keeping their eye on rising spending.

      Nov 12Barron'sMRNA
      Moderna Analyst Day: Details Strategic Shift Toward Oncology and Enhanced Production Capabilities
      Nov 12BenzingaMRNA
      Why is Moderna stock sliding today?
      Nov 12Investing.comMRNA
      Moderna Raises 2026 Revenue Growth Forecast to 15%–25% and Reports Progress in Cancer Vaccine Development
      Nov 12Yahoo FinanceMRNA
      Moderna preps Massachusetts facility as global supply site for cancer shot
      Nov 12Seeking AlphaMRNA
      Moderna raises 2026 revenue outlook, details growth strategy
      Nov 12Investing.comMRNA
      Moderna Outlines Next Phase of Growth at Analyst Day
      Nov 12Yahoo FinanceMRNA
      What Invesco S&P 500 Equal Weight ETF (RSP) Bought: Moderna Leads on Nov. 10
      Nov 12Yahoo FinanceMRNAIVZRSP
      MSCI announces November index changes, adds Moderna to World Index (MSCI:NYSE)

      MSCI's November 2026 review adds Moderna to the World Index and 10 stocks to its U.S. Prime Market 750, removing eight after Nov.

      Nov 12Seeking AlphaMRNAMSCI
      Moderna Earnings: Raising Fair Value Estimate as Steadying Demand for Respiratory Vaccines Supports Strong Quarter
      Nov 12MorningstarMRNA
      Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
      Nov 11Yahoo FinanceMRNA
      Moderna’s CEO eyes Keytruda-eclipsing future for personalised cancer vaccine
      Nov 11Yahoo FinanceMRNA
      Moderna chasing ‘holy grail’ of cancer prevention
      Nov 10Financial TimesMRNA
      Why is Moderna stock sliding today?
      Nov 10Investing.comMRNA
      Moderna to Present at Upcoming Conference in November 2026
      Nov 10Yahoo FinanceMRNA
      What Invesco S&P 500 Equal Weight ETF (RSP) Bought: Moderna Leads on Nov. 6
      Nov 10Yahoo FinanceMRNAIVZRSP
      Why is Moderna (MRNA) stock soaring today
      Nov 10Yahoo FinanceMRNA
      Is Moderna (MRNA) Priced For Too Much Sales Growth?
      Nov 9Yahoo FinanceMRNA
      Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy | The Motley Fool

      Revenue for the vaccine maker rose sharply in the third quarter, but it was largely due to COVID sales, which have been down significantly over the past five years.

      Nov 9The Motley FoolMRNA
      Moderna (MRNA) Stock Fair Value Rises After Intismeran Data And Q3 Beat
      Nov 9Yahoo FinanceMRNA
      Can Moderna's First Cancer Therapy Win FDA Approval in 2027?
      Nov 9Yahoo FinanceMRNA
      Moderna Soars Another 9% as Piper Sandler Lifts Target to $305 on Raised Outlook
      Nov 9Yahoo FinanceMRNAPIPR
      Moderna Earnings: Raising Fair Value Estimate as Steadying Demand for Respiratory Vaccines Supports Strong Quarter

      Moderna’s revenue growth also reflects revenue from international vaccine partnerships and the brightening US policy outlook.

      Nov 9MorningstarMRNA

      This is the newest page. Registered accounts read further back.